Summary:
A phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal study to evaluate the analgesic efficacy, safety, and tolerability of BEMA Buprenorphine in subjects with moderate to severe chronic low back pain.
Qualified Participants Must:
• Be 18 years of age or older
•
Have a diagnosis of moderate to severe low back pain for at least 6 months
Qualified Participants May Receive:
All study medication and procedures at no cost and compensation for time and travel.